Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
Add more filters

Country/Region as subject
Publication year range
1.
J Clin Densitom ; 17(2): 225-42, 2014.
Article in English | MEDLINE | ID: mdl-24690232

ABSTRACT

The International Society for Clinical Densitometry Official Revised Positions on reporting of densitometry results in children represent current expert recommendations to assist health care providers determine which skeletal sites should be measured, which, if any, adjustments should be made, reference databases to be used, and the elements to include in a dual-energy X-ray absorptiometry report. The recommended scanning sites remain the total body less head and the posterior-anterior spine. Other sites such as the proximal femur, lateral distal femur, lateral vertebral assessment, and forearm are discussed but are only recommended for specific pediatric populations. Different methods of interpreting bone density scans in children with short stature or growth delay are presented. The use of bone mineral apparent density and height-adjusted Z-scores are recommended as suitable size adjustment techniques. The validity of appropriate reference databases and technical considerations to consider when upgrading software and hardware remain unchanged. Updated reference data sets for all contemporary bone densitometers are listed. The inclusion of relevant demographic and health information, technical details of the scan, Z-scores, and the wording "low bone mass or bone density" for Z-scores less than or equal to -2.0 standard deviation are still recommended for clinical practice. The rationale and evidence for the development of the Official Positions are provided. Changes in the grading of quality of evidence, strength of recommendation, and worldwide applicability represent a change in current evidence and/or differences in opinion of the expert panelists used to validate the position statements for the 2013 Position Development Conference.


Subject(s)
Absorptiometry, Photon/standards , Adolescent , Age Determination by Skeleton/standards , Body Composition , Body Height , Child , Documentation/standards , Humans , Pediatrics/standards , Reference Values , Reproducibility of Results , Terminology as Topic
2.
Adv Simul (Lond) ; 9(1): 26, 2024 Jun 26.
Article in English | MEDLINE | ID: mdl-38918877

ABSTRACT

BACKGROUND: Recognizing and identifying latent safety threats (LSTs) before patient care commences is crucial, aiding leaders in ensuring hospital readiness and extending its impact beyond patient safety alone. This study evaluated the effectiveness of a combination of Simulation-based Clinical Systems Testing (SbCST) with Healthcare Failure Mode and Effect Analysis (HFMEA) with regard to mitigating LSTs within a newly constructed hospital. METHODS: Three phases of the combined SbCST and HFMEA approach were implemented across all hospital settings. The scenarios tested system functionalities, team responses, and resource availability. The threats thus identified were categorized into system-related issues, human issues, and resource issues, after which they were prioritized and addressed using mitigation strategies. Reassessment confirmed the effectiveness of these strategies before hospital commissioning. RESULTS: More than 76% of the LSTs were mitigated through the combined approach. System-related issues, such as nonfunctional communication devices and faulty elevators, were addressed by leadership. Human issues such as miscommunication and nonadherence to hospital policy led to improvements in interprofessional communication and teamwork. Resource issues, including missing equipment and risks of oxygen explosion, were addressed through procurement, maintenance, and staff training for equipment preparation. CONCLUSION: The SbCST and HFMEA were highly effective with regard to proactively identifying and mitigating LSTs across all aspects of hospital preparedness. This systematic and comprehensive approach offers a valuable tool for enhancing patient safety in new healthcare facilities, thereby potentially setting a new standard for proactive hazard identification and risk management in the context of healthcare construction and commissioning.

3.
Womens Health (Lond) ; 19: 17455057231158222, 2023.
Article in English | MEDLINE | ID: mdl-36869649

ABSTRACT

Vitamin D deficiency is prevalent worldwide. Since the discovery of the expression of vitamin D receptor in ventricular cardiomyocytes, fibroblasts, and blood vessels, there has been a growing body of literature assessing the link between vitamin D status and cardiovascular health from one side, and the effect of vitamin D supplementation on prevention of cardiovascular diseases from the other side. In this review, we summarized studies highlighting the role of vitamin D on cardiovascular health, namely atherosclerosis, hypertension, heart failure, and metabolic syndrome, a recognized significant risk factor for cardiovascular diseases. Studies showed discrepancies between findings from cross-sectional and longitudinal cohorts and those from interventional trials, but also between one outcome and another. Cross-sectional studies found a strong association between low 25 hydroxyvitamin D (25(OH)D3) and acute coronary syndrome, and heart failure. These findings encouraged the promotion for vitamin D supplementation as a preventive measure for cardiovascular diseases in the elderly, namely in women. This fact, however, turned out into a myth with the results of large interventional trials that did not show any benefit from vitamin D supplementation in reducing ischemic events, heart failure or its outcomes, or hypertension. Although some clinical studies showed beneficial effect of vitamin D supplementation on insulin sensitivity and metabolic syndrome, this effect was not consistent across all studies.


Subject(s)
Cardiovascular Diseases , Heart Failure , Hypertension , Metabolic Syndrome , Aged , Female , Humans , Cross-Sectional Studies , Vitamin D
4.
Simul Healthc ; 18(3): 191-202, 2023 Jun 01.
Article in English | MEDLINE | ID: mdl-35921616

ABSTRACT

SUMMARY STATEMENT: We performed a systematized review examining the existing literature on undergraduate healthcare students' perceptions and experiences with debriefing methods in simulation-based education. Twenty empirical research articles published in English between 2008 and 2020 were identified during a systematic search of 4 electronic databases. Data derived from these articles underwent critical appraisal and thematic analysis.Students valued the opportunity in debriefing for reflection, raising self-awareness of skills and learning. They preferred structured debriefing for promoting analytic skills and transfer of learning, favored video-assisted debriefing for fast recall and improving communication skills, and benefited most from instructor-led rather than peer-led debriefing. However, students appreciated group debriefing for aiding the construction of new understandings. There was no consensus on the preferred timing of debriefing, and students highlighted their concern about the disclosure of errors across different debriefing methods. Recommendations for educators to improve debriefing experiences and for future research are considered.


Subject(s)
Simulation Training , Students, Nursing , Humans , Clinical Competence , Delivery of Health Care , Learning , Simulation Training/methods , Students
5.
Cureus ; 15(8): e44471, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37791225

ABSTRACT

An enlarging sphenoid sinus mucocele can facilitate the growth of an intrasellar sinus mucocele. This subsequently leads to pituitary gland compression and endocrine abnormalities. We report the case of a 54-year-old man who underwent transsphenoidal resection of a non-secreting pituitary macroadenoma. Twenty years later he presented with headache, visual disturbances, erectile dysfunction, and poor libido and was diagnosed with a large sphenoid sinus mucocele that consequently extended into the sellar region. Based on the literature review, isolated intrasellar sinus mucocele post-transsphenoidal endoscopic surgery has been reported once. This is the first case of an intrasellar mucocele post-transsphenoidal resection to present with endocrine compromise on top of the compressive pituitary stalk symptoms.

6.
Metabolism ; 128: 154962, 2022 03.
Article in English | MEDLINE | ID: mdl-34958816

ABSTRACT

BACKGROUND: Aromatase inhibitors (AIs) are routinely used to treat postmenopausal women with early-stage breast cancer. Although AIs improve breast cancer outcomes, they increase the risk of osteoporosis and fractures. This systematic review and meta-analysis assesses the effect of antiresorptive drugs on AI induced bone loss in postmenopausal women with non-metastatic breast cancer. METHODS: We searched four databases until November 4th 2020. We included Randomized controlled trials (RCTs) of antiresorptive drugs in postmenopausal women with breast cancer treated with AI. Two authors screened studies, extracted data and assessed the risk of bias independently and in duplicate. RESULTS: We identified 14 RCTs: 7 on zoledronic acid, 6 on oral bisphosphonates and 1 on denosumab. The mean difference in bone mineral density (BMD) was 5% at the lumbar spine and 4% at the total hip, at 12 months, favoring zoledronic acid compared to control. The certainty of the evidence was low for lumbar spine and moderate for total hip BMD. Similarly, the mean difference was 3% at the lumbar spine and 2% at the total hip, favoring oral bisphosphonates with moderate certainty. The mean difference was 6% at the lumbar spine, and 4% at the total hip BMD favoring denosumab compared to placebo. In addition, zoledronic acid resulted in a mean difference in bone turnover marker levels of -35-41%, and the relarive risk for morphometric vertebral fractures was 0.7 [0.3-1.4], compared to control. Denosumab reduced fracture incidence by 50% compared to placebo. CONCLUSION: Evidence suggests a protective effect of antiresorptive drugs on BMD and bone turnover markers in postmenopausal women with non-metastatic breast cancer on AI. However, data on fracture risk reduction remains unclear.


Subject(s)
Aromatase Inhibitors/adverse effects , Bone Density Conservation Agents/therapeutic use , Breast Neoplasms/drug therapy , Osteoporosis, Postmenopausal/drug therapy , Bone Density/drug effects , Bone Remodeling/drug effects , Breast Neoplasms/pathology , Female , Humans , Neoplasm Staging
7.
J Clin Densitom ; 14(3): 240-62, 2011.
Article in English | MEDLINE | ID: mdl-21810532

ABSTRACT

Osteoporosis is a serious worldwide epidemic. Increased risk of fractures is the hallmark of the disease and is associated with increased morbidity, mortality and economic burden. FRAX® is a web-based tool developed by the Sheffield WHO Collaborating Center team, that integrates clinical risk factors, femoral neck BMD, country specific mortality and fracture data and calculates the 10 year fracture probability in order to help health care professionals identify patients who need treatment. However, only 31 countries have a FRAX® calculator at the time paper was accepted for publication. In the absence of a FRAX® model for a particular country, it has been suggested to use a surrogate country for which the epidemiology of osteoporosis most closely approximates the index country. More specific recommendations for clinicians in these countries are not available. In North America, concerns have also been raised regarding the assumptions used to construct the US ethnic specific FRAX® calculators with respect to the correction factors applied to derive fracture probabilities in Blacks, Asians and Hispanics in comparison to Whites. In addition, questions were raised about calculating fracture risk in other ethnic groups e.g., Native Americans and First Canadians. In order to provide additional guidance to clinicians, a FRAX® International Task Force was formed to address specific questions raised by physicians in countries without FRAX® calculators and seeking to integrate FRAX® into their clinical practice. The main questions that the task force tried to answer were the following: The Task Force members conducted appropriate literature reviews and developed preliminary statements that were discussed and graded by a panel of experts at the ISCD-IOF joint conference. The statements approved by the panel of experts are discussed in the current paper.


Subject(s)
Diagnosis, Computer-Assisted , Hip Fractures/diagnosis , Hip Fractures/ethnology , Osteoporotic Fractures/diagnosis , Osteoporotic Fractures/ethnology , Asian People , Black People , Bone Density , Femur Neck/diagnostic imaging , Femur Neck/pathology , Hispanic or Latino , Humans , Radiography , Risk Assessment
8.
J Med Liban ; 59(3): 117-21, 2011.
Article in English | MEDLINE | ID: mdl-22259897

ABSTRACT

BACKGROUND: Vascular calcifications are highly prevalent in patients maintained on chronic hemodialysis. They have been linked to numerous risk factors and have been associated with an increased risk of cardiovascular morbidity and mortality. The purpose of this pilot study is to assess the prevalence of vascular calcifications among dialysis patients in our tertiary care center and to identify the associated risk factors. METHODS: In the current study, we reviewed the charts of 43 patients undergoing hemodialysis at our center. We estimated the prevalence of vascular calcifications among dialysis patients using plain X-ray of the hand as the screening tool. We compared patient's characteristics and tried to identify possible risk factors, with a special emphasis on the subgroup of patients with diabetes. RESULTS: Vascular calcifications were prevalent among half of the patients on hemodialysis. Duration of dialysis (p = 0.02), diabetes (p < 0.001), and hypertension (p = 0.01) were highly associated with vascular calcifications. No association was found between vascular calcifications and age, gender, calcium-based phosphate binders, vitamin D supplementation, smoking, and lipid control. In multivariate analyses, diabetes and duration of dialysis were the only independent predictors of vascular calcifications and diabetics developed vascular calcifications earlier than nondiabetics (31 months vs 69 months). CONCLUSION: Vascular calcifications are moderately prevalent among patients undergoing hemodialysis at our center, and were found to be strongly correlated with diabetes and duration of dialysis. A larger, multicenter, prospective study should be conducted at national level, in order to confirm the findings of this study and to identify further modifiable risk factors, to decrease the incidence of vascular calcifications and the incurring cardiovascular morbidity and mortality in our population.


Subject(s)
Renal Dialysis , Vascular Calcification/diagnosis , Adult , Aged , Aged, 80 and over , Diabetes Mellitus , Female , Humans , Hypertension , Lebanon , Male , Middle Aged , Pilot Projects , Prevalence , Time Factors
9.
Int J Endocrinol ; 2021: 3170129, 2021.
Article in English | MEDLINE | ID: mdl-34462634

ABSTRACT

METHODS: A random sample of Lebanese adults residing in the Greater Beirut area was selected based on area probability and multistage cluster sampling. Data from 446 participants (68% females) with mean age 45.3 ± 15 years were used for the analyses. Participants were recruited between March and May. Serum 25-hydroxyvitamin D levels were measured using electrochemiluminescent immunoassay. RESULTS: Vitamin D deficiency was highly prevalent whether using the cutoff of 50 nmol/L or using the more conservative cutoff of 30 nmol/L; more specifically, 71.9% and 39.1% of the study population were deficient using the above cutoffs, respectively In the bivariate analyses, gender, BMI and body fat mass, socioeconomic factors (income and education level), alcohol consumption, dietary intake of fat and of vitamin D, serum LDL-cholesterol, and serum creatinine were all associated with vitamin D status. After adjustment for multiple covariates, age, income, alcohol consumption, and serum creatinine were independent predictors of vitamin D deficiency. CONCLUSION: Vitamin D deficiency is highly prevalent in Lebanon. Preventive measures should target the modifiable risk factors.

10.
J Clin Endocrinol Metab ; 106(9): e3644-e3654, 2021 08 18.
Article in English | MEDLINE | ID: mdl-33954783

ABSTRACT

CONTEXT: Guidelines for the dosage of vitamin D supplementation vary widely globally. OBJECTIVE: To investigate the impact of 2 vitamin D doses, bracketed between the IOM recommended dietary allowance (RDA) and the upper tolerable limit, on vitamin D nutritional status in elderly individuals. METHODS: This post hoc analysis of data collected from a 12-month, double-blind, randomized control trial included 221 ambulatory participants (≥ 65 years) with a mean BMI of 30.2 kg/m2 and a mean baseline serum 25-hydroxyvitamin D [25(OH)D] level of 20.4 ±â€…7.4 ng/mL, who were recruited from 3 outpatient centers in Lebanon. All participants received 1000 mg of elemental calcium daily from calcium citrate plus the daily equivalent of either 600 IU or 3750 IU of vitamin D3. RESULTS: Mean 25(OH)D level at 12 months was 26.0 ng/mL with low dose and 36.0 ng/mL with high dose vitamin D3. The proportion of participants reaching a value ≥ 20 ng/mL was 86% in the low dose, and 99% in the high dose arms, with no gender differences. The increment of 25(OH)D per 100 IU/day was 1 ng/mL with the low dose, and 0.41 ng/mL with the high dose. Serum 25(OH)D levels at 1 year were highly variable in both treatment arms. Baseline 25(OH)D level and vitamin D dose-but not age, BMI, gender, or season-were significant predictors of serum 25(OH)D level post-intervention. CONCLUSION: The IOM Recommended Dietary Allowance (RDA) of 600 IU/day does not bring 97.5% of ambulatory elderly individuals above the desirable threshold of 20 ng/mL. Country-specific RDAs are best derived taking into account the observed variability and predictors of achieved 25(OH)D levels.


Subject(s)
Cholecalciferol/administration & dosage , Cholecalciferol/therapeutic use , Obesity/drug therapy , Overweight/drug therapy , Vitamin D Deficiency/drug therapy , Vitamin D/analogs & derivatives , Vitamins/administration & dosage , Vitamins/therapeutic use , Aged , Aging , Body Mass Index , Calcium Citrate/therapeutic use , Dietary Supplements , Double-Blind Method , Female , Humans , Male , Obesity/complications , Overweight/complications , Recommended Dietary Allowances , Seasons , Sex Factors , Vitamin D/blood , Vitamin D Deficiency/complications
11.
Int J Neurosci ; 120(3): 206-10, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20374088

ABSTRACT

BACKGROUND: Multiple sclerosis (MS) has a variable disease course. Identifying early predictive prognostic factors is of paramount importance. Most of the data on these factors however comes from studies performed in western countries. Such data is lacking in the Arab World. The objective of this study is to identify early predictors of disability among MS patients in Lebanon. METHODS: 75 relapsing-remitting MS patients with 5 year follow-up from disease onset were selected from Project MS Lebanon database. The following parameters were studied as potential causes of early disability as defined by an EDSS > or = 3, after five years from disease onset: age at onset of MS, gender, interval between first and second attack, residual deficit after first attack, initial symptoms, treatment for at least 1 year in the first 5 years, and the number of relapses in the first 2 and 5 years. RESULTS: Patients with incomplete recovery from the first relapse were 11.66 times more likely to have a higher EDSS after 5 years (CI = 2.02-67.31, p = .001). Furthermore, the number of relapses during the first 5 years was also an independent predictor of EDSS > or = 3 at 5 years (p = .024). Other factors were not shown to predict a worse outcome. CONCLUSION: Overall, early predictors of disability in MS among the Lebanese population were not very different from similar predictors in western countries.


Subject(s)
Multiple Sclerosis/diagnosis , Adult , Age of Onset , Disability Evaluation , Female , Humans , Lebanon/epidemiology , Male , Middle Aged , Multiple Sclerosis/epidemiology , Multiple Sclerosis/physiopathology , Prognosis , Recurrence , Risk Factors , Severity of Illness Index , Sex Factors , Time Factors
12.
J Clin Densitom ; 12(4): 441-9, 2009.
Article in English | MEDLINE | ID: mdl-19766031

ABSTRACT

Children with malignancies have low bone mass. Pathways for metabolic bone disease were investigated in children with cancer by concomitantly assessing lifestyle, clinical, and biochemical predictors of bone mass. Forty-one children who were receiving cancer therapy for 61 weeks and 39 controls were studied. Data on lifestyle factors, biochemical and hormonal parameters, dual-energy X-ray absorptiometry bone mass measurements, body composition, and bone age were obtained. Compared with controls, patients had higher weight percentile and fat mass, a 6-month delay in bone age, and lower estradiol levels. They also had higher parathyroid hormone levels and lower bone remodeling markers and bone mass. Age, height, lean mass, fat mass, and bone maturation correlated positively with several bone mass variables, so did serum estradiol, testosterone, and markers of bone remodeling. Conversely, corticosteroids, methotrexate (MTX), and intrathecal therapy negatively correlated with bone mass at the spine and hip (R = -0.33 to 0.40, p < 0.04). In the adjusted analyses, bone maturation, serum osteocalcin level, MTX, and intrathecal therapy were significant predictors of lumbar spine and total body Z-scores, bone maturation accounting for the largest proportion in Z-score variance. Chemotherapy-induced delay in bone maturation and suppression of bone modeling are major pathophysiologic pathways predicting bone mass in children with malignancies.


Subject(s)
Absorptiometry, Photon/methods , Bone Density/physiology , Bone Diseases, Metabolic/diagnosis , Bone Remodeling/physiology , Models, Theoretical , Neoplasms/complications , Bone Diseases, Metabolic/etiology , Child , Cross-Sectional Studies , Female , Follow-Up Studies , Humans , Male , Prognosis , Retrospective Studies
13.
J Clin Densitom ; 11(3): 383-96, 2008.
Article in English | MEDLINE | ID: mdl-18448373

ABSTRACT

With the demographic explosion, the human, social, and economic costs of osteoporosis in developing countries, including the Middle East, will continue to rise. In 2002, the Lebanese Guidelines for Osteoporosis Assessment and Treatment were developed to optimize quality of osteoporosis care in Lebanon and the region. They were endorsed by 5 Lebanese medical scientific societies, and by the Eastern Mediterranean Regional Office branch of the World Health Organization (WHO). In April 2006, the Lebanese Society for Osteoporosis and Metabolic Bone Disorders (OSTEOS) led an initiative to update several recommendations detailed in the original document, based on relevant new local and international data. Data from a population-based sample of elderly Lebanese validated the following recommendations: fracture risk assessment, expressed as relative risk per standard deviation (RR/SD) decrease, was comparable in Lebanese subjects to similarly derived estimates from Western studies; the use of the NHANES database (hip), and the densitometer American database (spine) was as good, if not superior to the use of a Lebanese database for identifying subjects with prevalent vertebral fractures. The original recommendation regarding the use of a gender-specific western database, densitometer for spine and NHANES for T-score derivation for men, remains unchanged. For skeletal site selection, the update recommends measuring the spine and hip for women < or =65 yr, hip only for subjects >65 yr, and adding the forearm in conditions associated with cortical bone loss or in the case of inability to measure axial sites. The original recommendations for conservative management in premenopausal women were reiterated. This First Update of the Lebanese Osteoporosis Guidelines validates previous recommendations using evidence from a population-based sample of elderly Lebanese, and lays the ground for transitioning the Lebanese Osteoporosis Guidelines to the WHO global fracture risk assessment model.


Subject(s)
Osteoporosis/diagnosis , Osteoporosis/therapy , Practice Guidelines as Topic , Absorptiometry, Photon , Aged , Aged, 80 and over , Bone Density , Female , Fractures, Bone/epidemiology , Fractures, Bone/etiology , Humans , Lebanon/epidemiology , Logistic Models , Male , Risk Assessment , Risk Factors , World Health Organization
14.
Endocrine ; 59(1): 39-49, 2018 01.
Article in English | MEDLINE | ID: mdl-29030774

ABSTRACT

PURPOSE: In adults, growth hormone deficiency (GHD) has been associated with low bone mineral density (BMD), an effect counteracted by growth hormone (GH) replacement. Whether GH is beneficial in adults with age-related bone loss and without hypopituitarism is unclear. METHODS: We conducted a systematic literature search using Medline, Embase and the Cochrane Register of Controlled Trials. We extracted and analyzed data according to the bone outcome included [bone mineral content (BMC), BMD, and bone biomarker, fracture risk]. We performed a meta-analysis when possible. RESULTS: We included eight studies. Seven randomized 272 post-menopausal women, 61-69 years, to GH or control, for 6-24 months, and the eighth was an extension trial. Except for one study, all women received concurrent osteoporosis therapies. There was no significant effect of GH, as compared to control, on BMD at the lumbar spine (Weighted mean difference WMD = -0.01 [-0.04, 0.02]), total hip (WMD = 0 [-0.05, 0.06]) or femoral neck (WMD = 0 [-0.03, 0.04]). Similarly, no effect was seen on BMC. GH significantly increased the bone formation marker procollagen type-I carboxy-terminal propeptide (PICP) (WMD = 14.03 [2.68, 25.38]). GH resulted in a trend for increase in osteocalcin and in bone resorption markers. Patients who received GH had a significant decrease in fracture risk as compared to control (RR = 0.63 [0.46, 0.87]). Reported adverse events were not major, mostly related to fluid retention. CONCLUSION: GH may not improve bone density in women with age-related bone loss but may decrease fracture risk. Larger studies of longer duration are needed to further explore these findings in both genders, and to investigate the effect of GH on bone quality.


Subject(s)
Bone Density/drug effects , Human Growth Hormone/deficiency , Human Growth Hormone/pharmacology , Hypopituitarism/drug therapy , Osteoporosis/drug therapy , Osteoporotic Fractures/prevention & control , Aged , Female , Fractures, Bone/epidemiology , Fractures, Bone/prevention & control , Hormone Replacement Therapy , Humans , Hypopituitarism/complications , Middle Aged , Osteoporosis/complications , Osteoporosis/epidemiology , Osteoporotic Fractures/epidemiology , Osteoporotic Fractures/etiology , Randomized Controlled Trials as Topic/statistics & numerical data , Risk Factors
15.
Metabolism ; 89: 1-7, 2018 12.
Article in English | MEDLINE | ID: mdl-30227144

ABSTRACT

CONTEXT: Liquid Chromatography Mass Spectroscopy (LC-MS/MS) is the preferred method to measure 25 hydroxyvitamin D (25OHD) levels, but laboratories are increasingly adopting automated platform assays. OBJECTIVE: We assessed the performance of commonly used automated immunoassays, with that of LC-MS/MS, and the National Institute of Standards and Technology (NIST) reference values, to measure 25OHD levels. METHODS/SETTING: We compared serum 25OHD levels obtained from 219 elderly subjects, enrolled in a vitamin D trial, using the Diasorin Liaison platform assay, and the tandem LC-MS/MS method. We also assessed the performance of the Diasorin and Roche automated assays, expressed as mean % bias from the NIST standards, based on the vitamin D External Quality Assessment Scheme (DEQAS) reports, from 2013 to 2017. RESULTS: Serum 25OHD levels were significantly lower in the Diasorin compared to LC-MS/MS assay at baseline, 18.5 ±â€¯7.8 vs 20.5 ±â€¯7.6 ng/ml (p < 0.001), and all other time points. Diasorin (25OHD) = 0.76 × LC-MS/MS (25OHD) + 4.3, R2 = 0.596. The absolute bias was independent of 25OHD values, and the pattern unfit for any cross-calibration. The proportion of subjects considered for vitamin D treatment based on pre-set cut-offs differed significantly between the 2 assays. There also was wide variability in the performance of both automated assays, compared to NIST reference values. CONCLUSION: The performance of most widely used automated assays is sub-optimal. Our findings underscore the pressing need to re-consider current practices with regard to 25OHD measurements, interpretation of results from research studies, meta-analyses, the development of vitamin D guidelines, and their relevance to optimizing health.


Subject(s)
Clinical Decision-Making , Vitamin D Deficiency/blood , Vitamin D/analogs & derivatives , Aged , Automation , Chromatography, High Pressure Liquid , Female , Guidelines as Topic , Humans , Immunoassay , Luminescence , Male , Mass Spectrometry , Nutritional Status , Overweight/blood , Reference Values , Reproducibility of Results , Vitamin D/blood
16.
Bone ; 40(4): 1060-5, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17223616

ABSTRACT

Dual-energy X-ray absorptiometry (DXA) is the gold standard method for measurement of bone mineral density (BMD). The aims of the current study are to compare the ability of BMD measurements to identify subjects with vertebral fractures (VF), when the lumbar spine (LS), hip or both sites are measured. 460 subjects aged 73+/-5.2 years participated in the study. Thoraco-lumbar spine radiographs were obtained and analyzed for the presence of VF using the visual semi-quantitative assessment. BMD of the LS and the left femur were measured by DXA. Eighteen men (12%) and 56 women (20%) had at least one VF. 16% of scans at the LS were unreadable because of the presence of degenerative changes. In both genders, BMD of the hip showed better ability than LS BMD in detecting subjects with osteoporosis. BMD and T-score values at the hip, but not the LS, were lower in subjects with VF than those without (p<0.05). Femoral neck BMD showed the highest OR for each S.D. decrease in BMD for identifying subjects with VF, and the best predictability for prevalent VF using ROC. Fracture risk prediction did not increase by adding the spine to the hip measurement. In conclusion, hip BMD was the only and best skeletal site needed to detect subjects with osteoporosis and showed the strongest relationship with prevalent vertebral fractures in elderly subjects.


Subject(s)
Absorptiometry, Photon/methods , Fractures, Bone/diagnosis , Osteoporosis/diagnosis , Aged , Aged, 80 and over , Bone Density , Female , Fractures, Bone/metabolism , Hip Joint/metabolism , Humans , Male , Osteoporosis/metabolism , Risk Factors , Spinal Fractures/diagnosis , Spinal Fractures/metabolism , Spine/metabolism
17.
Bone ; 40(4): 1066-72, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17236834

ABSTRACT

The International Osteoporosis Foundation recommends using a universal database i.e. the NHANES database for the diagnosis of osteoporosis. Population-based databases for T-score calculation are still debated in terms of clinical and public health relevance. The current study aimed at estimating the prevalence of vertebral fractures in the Lebanese elderly, determining BMD-fracture relationship, and assessing the effect of database selection on osteoporosis prevalence and fracture risk assessment. Apparently healthy subjects were randomly selected from the Greater Beirut area - one-third of the Lebanese population at large - using a multilevel cluster technique. Subjects with medical conditions likely to affect bone metabolism i.e. history of major chronic disease, intake of medications that affect bone metabolism were excluded. Presence of vertebral fracture was estimated by a semi-quantitative assessment. Bone density was measured by central DXA. Clinical risk factors included age, gender, height, weight, body mass index, smoking, exercise, falls, previous fragility fracture and family history of fragility fracture. Impact of database selection was assessed by: (1) Comparison of sensitivity and specificity for prevalent vertebral fractures of the T-score

Subject(s)
Osteoporosis/complications , Spinal Fractures/etiology , Absorptiometry, Photon , Aged , Aged, 80 and over , Bone Density , Databases, Factual , Female , Humans , Lebanon/epidemiology , Male , Osteoporosis/epidemiology , Osteoporosis/metabolism , Spinal Fractures/epidemiology
18.
Int Surg ; 92(6): 327-30, 2007.
Article in English | MEDLINE | ID: mdl-18402125

ABSTRACT

We present in this report two cases of papillary carcinoma arising in a thyroglossal duct cyst. The first case was a 32-year-old female patient who presented with a neck mass of 5 years' duration that had recently increased in size. The patient was otherwise asymptomatic. The second patient was a 41-year-old male patient who presented with a submental mass that had been growing over the previous several months. Associated symptoms included local symptoms such as dysphagia and hoarseness and general symptoms such as fatigue and weight loss. Pathological examination revealed the presence of papillary carcinoma in the mass with presence of focus of papillary carcinoma in the thyroid bed in both cases. Periosseous invasion of the hyoid bone and involvement of the submandibular lymph nodes were observed in the second patient. The patients underwent total thyroidectomy with lymph node dissection followed by radioactive iodine therapy and are currently on thyroxin replacement.


Subject(s)
Thyroglossal Cyst/complications , Thyroid Neoplasms/pathology , Adult , Carcinoma, Papillary/secondary , Carcinoma, Papillary/surgery , Cell Transformation, Neoplastic , Female , Humans , Male , Thyroglossal Cyst/surgery , Thyroid Neoplasms/surgery , Thyroidectomy
19.
Article in English | MEDLINE | ID: mdl-28993757

ABSTRACT

A 56-year-old middle-eastern male with a long-standing history of poorly controlled type 2 diabetes mellitus presented to us complaining of severely painful bilateral upper and lower extremity cramps occurring shortly after his rapid-acting insulin analog injection(s). The cramps had started 6 months ago and have been occurring intermittently in non-predictable episodes since then. He had otherwise never experienced any insulin-related adverse reaction(s) before. His cramps are very painful and debilitating, interfering with his daily activities and placing him in a state of constant fear/anxiety of re-experiencing them. This caused him to become non-adherent with his prescribed treatment and poorly compliant with his follow-up regimens. Thorough examination showed a diffuse loss of sensation over the lower limbs. This was subsequently confirmed with a combined electromyography-nerve conduction study which indicated extensive diabetic axonal polyneuropathy. By contrast, lower extremity segmental arterial pressures were negative for peripheral vasculo-occlusive disease, ruling out vascular insufficiency as a possible etiology of the cramps. We then measured the levels of serum electrolytes right-before and 30 min right-after injecting the patient with his insulin. Potassium dropped by about 16% from its initial level, compared to a drop of only around 4% for calcium and none (0%) for magnesium. Thus, we speculated this insulin-induced sharp drop in serum potassium levels as potentiating the patient's already existing advanced diabetic neuropathy, thereby leading to muscle cramping. However, attempting potassium supplementation for a brief period of time led to a rapid resolution of cramps when they occurred and an overall reduction in their frequency of recurrence. This tilted our diagnosis toward the insulin-induced acute drop in serum potassium levels as the most likely etiology underlying the patient's cramps. Such an observation has been made only once previously within the literature, back in 1992, at the Duke University Medical Center.

20.
Metabolism ; 70: 160-176, 2017 May.
Article in English | MEDLINE | ID: mdl-28403940

ABSTRACT

INTRODUCTION: Hypovitaminosis D affects one-third to two-thirds of children and pregnant women from the Middle East and North Africa (MENA) region. OBJECTIVE: To evaluate in infants, children, adolescents and pregnant women, from the MENA region, the effect of supplementation with different vitamin D doses on the change in 25-hydroxyvitamin D [25(OH)D] level reached, and other skeletal and non-skeletal outcomes. METHODS: This is a systematic review of randomized controlled trials of vitamin D supplementation conducted in the MENA region. We conducted a comprehensive literature search in 7 databases, without language or time restriction, until November 2016. Two reviewers abstracted data from the included studies, independently and in duplicate. We calculated the mean difference (MD) and 95% CI of 25(OH)D level reached when at least 2 studies were eligible in each comparison (low (<800IU), intermediate (800-2000IU) or high (>2000IU) daily dose of vitamin D, or placebo). We pooled data using RevMan version 5.3. RESULTS: We identified a total of 15 eligible trials: one in infants, 4 in children and adolescents and 10 in pregnant women. In children and adolescents, an intermediate vitamin D dose (1901IU/d), resulted in a mean difference in 25(OH)D level of 13.5 (95% confidence interval (CI) 8.1-18.8) ng/ml, compared to placebo, favoring the intermediate dose (p<0.001). The proportion of children and adolescents reaching a 25(OH)D level≥ 20ng/ml was 74% in the intermediate dose group. In pregnant women, four trials started supplementation at 12-16weeks of gestation and continued until delivery, and six trials started supplementation at 20-28weeks' gestation and stopped it at delivery. The MD in 25(OH)D level reached was 8.6 (95% CI 5.3-11.9) ng/ml (p<0.001) comparing the high dose (3662IU/d) to the intermediate dose (1836IU/d), and 12.3 (95% CI 6.4-18.2) ng/ml (p<0.001), comparing the high dose (3399IU/d) to the low dose (375IU/d). Comparing the intermediate (1832IU/d) to the low dose (301IU/d), the MD in 25(OH)D level achieved was 7.8 (95% CI 4.5-10.8) ng/ml (p<0.001). The proportion of pregnant women reaching a 25(OH)D level≥20ng/ml was 80%-90%, 73% and 27%-43% in the high, intermediate, and low dose groups, respectively. The risk of bias in the included studies, for children, adolescents and pregnant women, ranged from low to high across all doamins. CONCLUSION: In children, adolescents and pregnant women from the MENA, an intermediate vitamin D dose of 1000-2000IU daily may be necessary to allow for the majority of the population to reach a desirable 25(OH)D level of 20ng/ml. Further high quality RCTs are required to confirm/refute the beneficial impact of vitamin D supplementation on various clinically important outcomes.


Subject(s)
Vitamin D/analogs & derivatives , Vitamin D/administration & dosage , Adolescent , Adult , Africa, Northern , Child , Dietary Supplements , Female , Humans , Infant , Middle East , Practice Guidelines as Topic , Pregnancy , Randomized Controlled Trials as Topic , Vitamin D/blood
SELECTION OF CITATIONS
SEARCH DETAIL